Cost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe
Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying...
Saved in:
| Published in | Respiratory medicine Vol. 101; no. 9; pp. 1885 - 1894 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Elsevier Ltd
01.09.2007
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax® in four Southern European countries. Methods A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax® . Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Results Grazax® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. Conclusion The analysis illustrates that allergen SIT with Grazax® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. |
|---|---|
| AbstractList | Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax® in four Southern European countries. Methods A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax® . Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Results Grazax® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. Conclusion The analysis illustrates that allergen SIT with Grazax® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax® in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax® . Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax® was cost-effective for all countries for an annual price in the range of &z.euro;1500-&z.euro;1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. BACKGROUNDAllergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax in four Southern European countries.METHODSA prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs).RESULTSGrazax was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax was cost-effective for all countries for an annual price in the range of 1500 euros - 1900 euros. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season.CONCLUSIONThe analysis illustrates that allergen SIT with Grazax for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax was cost-effective for all countries for an annual price in the range of 1500 euros - 1900 euros. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax ® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax ® in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax ®. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax ® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax ® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax ® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. |
| Author | Canonica, G.W Poulsen, P.B Vestenbæk, U |
| Author_xml | – sequence: 1 fullname: Canonica, G.W – sequence: 2 fullname: Poulsen, P.B – sequence: 3 fullname: Vestenbæk, U |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18987438$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17611095$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt2K1DAUx4OsuLOrL-CFFETvWk8-mrYgwjCsq7AguAriTWjTEze1k9SkXdiX8iF8MlNmcGEvvErI_3c-cv7njJw475CQ5xQKClS-GYqwx75gAFUBZQHAH5ENLTnLOUhxQjbQlCKXlNJTchbjAACNEPCEnNIqvSZ1Q8adj3OOxqCe7S06jDHzJrv8vP2-_fbnd2Z8yKaASZmtd6v0I7SJmfw4osus6xeNfRZurPPau2Fxax4725i07Nov8w0Gl10swU_4lDw27Rjx2fE8J1_fX3zZfcivPl1-3G2vcl1W1Zx32rRNDQ1jVFaNBMZaDZgu2gDjsoFONrIyyEAylH1tGC-xxUp3ZcdBlPycvD7knYL_tWCc1d5GjePYOvRLVLKmXDAhE_jyATj4JbjUm6LASxAVEzxR7EDp4GMMaNQU7L4NdwlSqxNqUKsTanVCQamSEynoxTH10q3av5Dj6BPw6gi0UbejCa3TNt5zdVNXgteJe3vgME3s1mJQUVt0aeo2JNNU7-3_-3j3IFyP1tlU8SfeYbz_r4pMgbped2ZdGagAaAOC_wW6Ib3t |
| CitedBy_id | crossref_primary_10_1016_j_alit_2021_11_002 crossref_primary_10_3310_hta20670 crossref_primary_10_1097_MOO_0000000000000150 crossref_primary_10_1111_all_14246 crossref_primary_10_1111_j_1398_9995_2012_02861_x crossref_primary_10_1186_1939_4551_7_6 crossref_primary_10_1016_j_jaci_2010_09_033 crossref_primary_10_4137_EHI_S16486 crossref_primary_10_1111_all_13254 crossref_primary_10_1007_s40273_013_0084_z crossref_primary_10_1016_j_jval_2020_06_001 crossref_primary_10_2165_00151234_200705370_00017 crossref_primary_10_1016_j_jaci_2010_09_037 crossref_primary_10_1016_j_jaci_2015_12_1300 crossref_primary_10_33590_emj_10314632 crossref_primary_10_1111_j_1398_9995_2009_02232_x crossref_primary_10_1007_s11882_019_0893_z crossref_primary_10_1016_j_mcna_2019_09_001 crossref_primary_10_3111_13696998_2012_688904 crossref_primary_10_1016_j_iac_2019_09_003 crossref_primary_10_1097_ACI_0000000000000785 crossref_primary_10_1016_j_jaci_2011_10_045 crossref_primary_10_1097_01_WOX_0000365038_00251_8a crossref_primary_10_1016_j_drudis_2015_07_010 crossref_primary_10_1097_ACI_0b013e32831411e9 crossref_primary_10_1097_01_WOX_0000365049_40480_36 crossref_primary_10_1111_j_1365_2222_2011_03794_x crossref_primary_10_1080_09286586_2020_1792938 crossref_primary_10_1186_1710_1492_6_29 crossref_primary_10_1111_all_13201 crossref_primary_10_1016_S1081_1206_10_60498_X crossref_primary_10_1080_1744666X_2021_1886079 crossref_primary_10_2332_allergolint_08_OA_0032 crossref_primary_10_1111_all_15985 crossref_primary_10_1111_j_1398_9995_2011_02590_x crossref_primary_10_2217_imt_2022_0143 crossref_primary_10_1016_S1081_1206_10_60190_1 crossref_primary_10_1371_journal_pone_0131949 crossref_primary_10_1097_WOX_0b013e3181c6c379 crossref_primary_10_1097_WOX_0b013e31816d92d6 crossref_primary_10_1097_01_WOX_0000365050_48103_34 crossref_primary_10_1248_yakushi_130_1725 crossref_primary_10_1186_s12948_016_0057_9 crossref_primary_10_1097_ACI_0b013e3283196a9b crossref_primary_10_1186_s13601_015_0045_z crossref_primary_10_1186_s12948_015_0016_x |
| Cites_doi | 10.1067/mai.2002.121317 10.1136/bmj.302.6771.265 10.1034/j.1398-9995.2002.23664.x 10.1056/NEJM199908123410702 10.1016/S1081-1206(10)63282-6 10.1038/sj.jhh.1001178 10.2165/00019053-199507010-00001 10.2165/00019053-200017010-00002 10.1183/09031936.02.02542001 10.1111/j.1398-9995.1988.tb01631.x 10.2174/187152806775269286 10.1177/009286150103500122 10.1111/j.1398-9995.1998.tb03886.x 10.1067/mai.2001.118891 10.1016/0168-8510(96)00822-6 10.1378/chest.111.2_Supplement.11S 10.2165/00019053-199508030-00007 10.1183/09031936.04.00116203 10.1016/j.jaci.2005.12.1358 10.1111/j.1398-9995.2005.00949.x 10.1111/j.1398-9995.2003.00468.x 10.1053/rmed.2001.1031 10.1183/09031936.04.00013904 10.1046/j.1365-2222.2003.01587.x 10.1111/j.1398-9995.2006.01068.x 10.1016/j.jaci.2006.01.023 10.1016/S1081-1206(10)63136-5 10.1016/S0091-6749(98)70218-0 10.1016/j.jaci.2004.07.012 10.1542/peds.2004-2709 10.1183/09031936.98.12061322 10.1067/mai.2003.129 10.1111/j.1742-1241.2005.00347.x 10.1111/j.1398-9995.2006.01053.x 10.1183/09031936.04.00004904 10.1007/s11136-006-9110-3 10.1016/j.jaci.2006.05.003 10.3833/pdr.v2005i64.620 10.1111/j.1398-9995.1995.tb01170.x 10.1016/S1081-1206(10)61090-3 |
| ContentType | Journal Article |
| Copyright | 2007 2007 INIST-CNRS Copyright Elsevier Limited Sep 2007 |
| Copyright_xml | – notice: 2007 – notice: 2007 INIST-CNRS – notice: Copyright Elsevier Limited Sep 2007 |
| DBID | 6I. AAFTH IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| DOI | 10.1016/j.rmed.2007.05.003 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Virology and AIDS Abstracts British Nursing Index British Nursing Index (BNI) (1985 to Present) AIDS and Cancer Research Abstracts British Nursing Index ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-3064 |
| EndPage | 1894 |
| ExternalDocumentID | 2745006421 10_1016_j_rmed_2007_05_003 17611095 18987438 S0954611107001904 1_s2_0_S0954611107001904 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GroupedDBID | - 08R 0R 1 1- 123 1B1 1P 1RT 1~. 1~5 29P 3O- 3V. 4.4 457 4G. 53G 55 5RE 5VS 6I. 7-5 71M 7RV 7X7 8P 9JM AABNK AACTN AAEDT AAFTH AAIAV AAIKJ AAKOC AALMO AALRI AAOAW AAPBV AAQFI AAQXK AAXUO ABBQC ABFLS ABFNM ABFRF ABLVK ABMAC ABMZM ABOCM ABPIF ABQIS ABVKL ABWYI ABXDB ABYKQ ACDAQ ACGFO ACGFS ACPRK ACRLP ADALY ADBBV ADEZE ADFRT AEBSH AEFWE AEKER AENEX AEVXI AEXQZ AFCTW AFFNX AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AZFZN BBAFP BENPR BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI CAG COF CS3 DU5 EBS EFJIC EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FO G- G-2 G-Q GBLVA GJ HEJ HMK HMO HVGLF HZ IHE IPNFZ IXB J1W K K-O KOM L7B LCYCR M M0T M29 M2O M41 MO0 N9A NCXOZ O-L O9- OAUVE OI- OK1 OU. OZT P-8 P-9 P2P PC. PQEST PQQKQ PQUKI PROAC Q38 R2- RIG ROL RPZ RSU SAE SDF SDG SEL SES SEW SPCBC SSH SSZ SV3 T5K UHS UV1 WH7 WOW WUQ X7M Z5R ZA5 ZGI ZXP --- --K --M .1- .55 .FO .GJ .~1 0R~ 1P~ 8P~ AAEDW ABJNI ADMUD AHPSJ AXJTR EFLBG FYGXN HZ~ ~G- AAUGY AKALU IQODW 0SF AAXKI ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c577t-bcfa98092216796022ac0e960cf023690b6967fe2062e6d8f235eae7cb5b30453 |
| IEDL.DBID | IXB |
| ISSN | 0954-6111 |
| IngestDate | Fri Aug 16 10:15:25 EDT 2024 Fri Sep 13 10:27:57 EDT 2024 Thu Sep 26 17:11:01 EDT 2024 Sat Sep 28 07:43:13 EDT 2024 Sun Oct 22 16:03:10 EDT 2023 Fri Feb 23 02:31:37 EST 2024 Thu Aug 18 17:14:29 EDT 2022 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | QALY Grass pollen allergy Rhinoconjunctivitis Allergen specific immunotherapy Cost-effectiveness Grass allergen tablet Allergy Nose disease Rhinitis Conjunctiva disease Conjunctivitis Prevention Immunotherapy ENT disease Tablet Pollen Public health Cost efficiency analysis Pneumology Immunopathology South Eye disease Treatment Health economy Dosage form Allergen |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c577t-bcfa98092216796022ac0e960cf023690b6967fe2062e6d8f235eae7cb5b30453 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0954611107001904 |
| PMID | 17611095 |
| PQID | 1035047243 |
| PQPubID | 1216389 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_68134246 proquest_journals_1035047243 crossref_primary_10_1016_j_rmed_2007_05_003 pubmed_primary_17611095 pascalfrancis_primary_18987438 elsevier_sciencedirect_doi_10_1016_j_rmed_2007_05_003 elsevier_clinicalkeyesjournals_1_s2_0_S0954611107001904 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-09-01 |
| PublicationDateYYYYMMDD | 2007-09-01 |
| PublicationDate_xml | – month: 09 year: 2007 text: 2007-09-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Respiratory medicine |
| PublicationTitleAlternate | Respir Med |
| PublicationYear | 2007 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Dahl, Stender, Rak (bib24) 2006; 61 Antonicelli, Bucca, Neri (bib41) 2004; 23 Durham, Yang, Pedersen, Johansen, Rak (bib23) 2006; 117 Bousquet, Lockey, Malling (bib11) 1998; 81 Sculpher (bib48) 2006; 61 Donahue, Greineder, Connor-Lacke, Canning, Platt (bib51) 1999; 82 Durham, Walker, Varga (bib14) 1999; 34 Drummond, Sculpher, Torrance, O′Brien, Stoddart (bib32) 2005 Instituto Nacional de Meteorologia. El año más seco, Noticias; 2006. Guide to the methods of technology appraisal. National Institute of Clinical Excellence, April 2004. Stock, Redaelli, Luengen, Wendland, Civello, Lauterbach (bib42) 2005; 25 Varney, Gaga, Frew, Aber, Kay, Durham (bib12) 1991; 302 Serra-Batles, Plaza, Morejon, Comella (bib37) 1998; 12 Canonica, Passalacqua (bib20) 2003; 111 Lindgren, Sears, Campbell, Villasante, Huang, Lindh (bib35) 2005; 59 Conference report, Scottish medicines consortium completes four year's work, vol. 10(1). IMS Health, PHARMA Pricing & Reimbursement; 2006. Berto, Passalacqua, Crimi (bib22) 2006; 97 Garattini, Grilli, Scopelliti, Mantovani (bib28) 1995; 7 Van Ganse, Laforest, Pietri (bib38) 2002; 20 . Rak, Yang, Pedersen, Durham (bib25) 2007; 16 Grossman (bib8) 1997; 111 Collége des Èconomistes de la Santé (CES). French guidelines for the economic evaluation of health care technologies, September 2004. Marshall JB. European allergy white paper. Allergic diseases as a public health problem in Europe. The UCG Institute of Allergy, May 1997. Di-Rienzo, Marcucci, Puccinelli (bib15) 2003; 33 Walker, Varney, Gaga, Jacobson, Durham (bib13) 1995; 50 Möller, Dreborg, Ferdousi (bib16) 2002; 109 Niggemann, Jacobsen, Dreborg (bib17) 2006; 61 Linneberg, Nielsen, Frølund, Madsen, Dirksen, Jørgensen (bib6) 2002; 57 Dahl, Kapp, Colombo (bib26) 2006; 118 EFA (European Federation of Allergy and Airway Diseases Patients Association). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report; 2005. Galassi, De Sario, Biggeri (bib4) 2006; 117 Heyse, Cook, Carides (bib43) 2001 Capri, Ceci, Terranova, Merlo, Mantovani (bib27) 2001; 35 Gonzáles Minero, Candau, Thomás, Morales (bib47) 1998; 53 Pinotti M, Vercilli F. Nuovo nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Direzione Medica di Presidio; 2004. Royal College of Physicians. Allergy: the unmet need, a blueprint for better patient care, June 2003. Mosbech, Østerballe (bib33) 1988; 43 Bauchau, Durham (bib3) 2004; 24 Coons, Rao, Keininger, Hays (bib44) 2000; 17 Valovirta, Jacobsen, Niggemann (bib18) 2006; 117 Brooks (bib45) 1996; 37 Rovira, Antoñanzas (bib29) 1995; 8 Bousquet, van Cauwenberge, Khaltaev (bib1) 2001; 108 Linneberg, Nielsen, Madsen, Frølund, Dirksen, Jørgensen (bib39) 2001; 95 ALK-Abelló. GT-08 Integrated clinical trial report, pollen season 2005. Final 16, October 2005. Bousquet (bib10) 2004; 59 Degli Esposti, Berto, Ruffo, Buda, Degli Esposti, Sturani (bib34) 2001; 15 Passalacqua, Guerra, Pasquali, Canonica (bib21) 2006; 5 Bousquet J, van Cauwenberge PB, Khaltaev N, et al. The management of allergic rhinitis symptoms in the pharmacy, Paris, October 23, 2002. Novembre, Galli, Landi (bib40) 2004; 114 Corren (bib7) 1998; 101 Rak (10.1016/j.rmed.2007.05.003_bib25) 2007; 16 Rovira (10.1016/j.rmed.2007.05.003_bib29) 1995; 8 Drummond (10.1016/j.rmed.2007.05.003_bib32) 2005 Walker (10.1016/j.rmed.2007.05.003_bib13) 1995; 50 Berto (10.1016/j.rmed.2007.05.003_bib22) 2006; 97 Bousquet (10.1016/j.rmed.2007.05.003_bib11) 1998; 81 10.1016/j.rmed.2007.05.003_bib46 Garattini (10.1016/j.rmed.2007.05.003_bib28) 1995; 7 10.1016/j.rmed.2007.05.003_bib2 Coons (10.1016/j.rmed.2007.05.003_bib44) 2000; 17 Brooks (10.1016/j.rmed.2007.05.003_bib45) 1996; 37 10.1016/j.rmed.2007.05.003_bib5 10.1016/j.rmed.2007.05.003_bib9 Bousquet (10.1016/j.rmed.2007.05.003_bib10) 2004; 59 Lindgren (10.1016/j.rmed.2007.05.003_bib35) 2005; 59 Serra-Batles (10.1016/j.rmed.2007.05.003_bib37) 1998; 12 Capri (10.1016/j.rmed.2007.05.003_bib27) 2001; 35 Gonzáles Minero (10.1016/j.rmed.2007.05.003_bib47) 1998; 53 Bousquet (10.1016/j.rmed.2007.05.003_bib1) 2001; 108 Galassi (10.1016/j.rmed.2007.05.003_bib4) 2006; 117 10.1016/j.rmed.2007.05.003_bib49 Grossman (10.1016/j.rmed.2007.05.003_bib8) 1997; 111 Dahl (10.1016/j.rmed.2007.05.003_bib26) 2006; 118 Corren (10.1016/j.rmed.2007.05.003_bib7) 1998; 101 Heyse (10.1016/j.rmed.2007.05.003_bib43) 2001 Antonicelli (10.1016/j.rmed.2007.05.003_bib41) 2004; 23 Novembre (10.1016/j.rmed.2007.05.003_bib40) 2004; 114 10.1016/j.rmed.2007.05.003_bib50 Möller (10.1016/j.rmed.2007.05.003_bib16) 2002; 109 Linneberg (10.1016/j.rmed.2007.05.003_bib39) 2001; 95 Linneberg (10.1016/j.rmed.2007.05.003_bib6) 2002; 57 Di-Rienzo (10.1016/j.rmed.2007.05.003_bib15) 2003; 33 10.1016/j.rmed.2007.05.003_bib19 Stock (10.1016/j.rmed.2007.05.003_bib42) 2005; 25 Niggemann (10.1016/j.rmed.2007.05.003_bib17) 2006; 61 Canonica (10.1016/j.rmed.2007.05.003_bib20) 2003; 111 Sculpher (10.1016/j.rmed.2007.05.003_bib48) 2006; 61 Valovirta (10.1016/j.rmed.2007.05.003_bib18) 2006; 117 Varney (10.1016/j.rmed.2007.05.003_bib12) 1991; 302 Donahue (10.1016/j.rmed.2007.05.003_bib51) 1999; 82 Durham (10.1016/j.rmed.2007.05.003_bib14) 1999; 34 Durham (10.1016/j.rmed.2007.05.003_bib23) 2006; 117 Bauchau (10.1016/j.rmed.2007.05.003_bib3) 2004; 24 Passalacqua (10.1016/j.rmed.2007.05.003_bib21) 2006; 5 Van Ganse (10.1016/j.rmed.2007.05.003_bib38) 2002; 20 Degli Esposti (10.1016/j.rmed.2007.05.003_bib34) 2001; 15 10.1016/j.rmed.2007.05.003_bib36 10.1016/j.rmed.2007.05.003_bib31 10.1016/j.rmed.2007.05.003_bib30 Dahl (10.1016/j.rmed.2007.05.003_bib24) 2006; 61 Mosbech (10.1016/j.rmed.2007.05.003_bib33) 1988; 43 |
| References_xml | – volume: 15 start-page: 329 year: 2001 end-page: 334 ident: bib34 article-title: The PANDORA project: results of the cost of illness analysis publication-title: J Hum Hypertension contributor: fullname: Sturani – volume: 33 start-page: 206 year: 2003 end-page: 210 ident: bib15 article-title: Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study publication-title: Clin Exp Allergy contributor: fullname: Puccinelli – volume: 108 start-page: S147 year: 2001 end-page: S334 ident: bib1 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol contributor: fullname: Khaltaev – volume: 37 start-page: 53 year: 1996 end-page: 72 ident: bib45 article-title: EuroQol: the current state of play publication-title: Health Policy contributor: fullname: Brooks – volume: 35 start-page: 189 year: 2001 end-page: 201 ident: bib27 article-title: Guidelines for economic evaluation in Italy: recommendations from the Italian group of pharmacoeconomic studies publication-title: Drug Inf J contributor: fullname: Mantovani – volume: 61 start-page: 527 year: 2006 end-page: 530 ident: bib48 article-title: The use of quality-adjusted life-years in cost-effectiveness studies publication-title: Allergy contributor: fullname: Sculpher – volume: 111 start-page: 437 year: 2003 end-page: 448 ident: bib20 article-title: Noninjection routes for immunotherapy publication-title: J Allergy Clin Immunol contributor: fullname: Passalacqua – volume: 53 start-page: 266 year: 1998 end-page: 274 ident: bib47 article-title: Airborne grass (Poaceae) pollen in southern Spain. Results of a 10-year study (1987–1996) publication-title: Allergy contributor: fullname: Morales – volume: 12 start-page: 1322 year: 1998 end-page: 1326 ident: bib37 article-title: Brugues J: cost of asthma according to the degree of severity publication-title: Eur Respir J contributor: fullname: Comella – volume: 61 start-page: 185 year: 2006 end-page: 190 ident: bib24 article-title: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis publication-title: Allergy contributor: fullname: Rak – volume: 109 start-page: 251 year: 2002 end-page: 256 ident: bib16 article-title: Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis. The PAT-study publication-title: J Allergy Clin Immunol contributor: fullname: Ferdousi – volume: 117 start-page: 721 year: 2006 ident: bib18 article-title: A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study publication-title: J Allergy Clin Immunol contributor: fullname: Niggemann – volume: 114 start-page: 851 year: 2004 end-page: 857 ident: bib40 article-title: Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol contributor: fullname: Landi – volume: 59 start-page: 62 year: 2005 end-page: 68 ident: bib35 article-title: Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and Spain publication-title: Int J Clin Practice contributor: fullname: Lindh – volume: 34 start-page: 468 year: 1999 end-page: 475 ident: bib14 article-title: Long-term clinical efficacy of grass-pollen allergen specific immunotherapy publication-title: N Engl J Med contributor: fullname: Varga – volume: 117 start-page: 34 year: 2006 end-page: 42 ident: bib4 article-title: Changes in the prevalence of asthma and allergies among children and adolescents in Italy: 1999–2002 publication-title: Pediatrics contributor: fullname: Biggeri – volume: 16 start-page: 191 year: 2007 end-page: 201 ident: bib25 article-title: Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study publication-title: Qual Life Res contributor: fullname: Durham – volume: 118 start-page: 434 year: 2006 end-page: 440 ident: bib26 article-title: Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol contributor: fullname: Colombo – volume: 7 start-page: 1 year: 1995 end-page: 6 ident: bib28 article-title: A proposal for Italian Guidelines in pharmacoeconomics publication-title: Pharmacoeconomics contributor: fullname: Mantovani – volume: 5 start-page: 43 year: 2006 end-page: 51 ident: bib21 article-title: Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy publication-title: Inflamm Allergy Drug Targets contributor: fullname: Canonica – volume: 117 start-page: 802 year: 2006 end-page: 809 ident: bib23 article-title: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol contributor: fullname: Rak – volume: 57 start-page: 1048 year: 2002 end-page: 1052 ident: bib6 article-title: The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study publication-title: Allergy contributor: fullname: Jørgensen – volume: 20 start-page: 260 year: 2002 end-page: 267 ident: bib38 article-title: Persistent asthma: disease control, resource utilisation and direct costs publication-title: Eur Respir J contributor: fullname: Pietri – volume: 59 start-page: 373 year: 2004 end-page: 387 ident: bib10 article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma publication-title: Allergy contributor: fullname: Bousquet – year: 2005 ident: bib32 article-title: Methods for the economic evaluation of health care programmes contributor: fullname: Stoddart – volume: 111 start-page: 6 year: 1997 end-page: 11 ident: bib8 article-title: One airway, one disease publication-title: Chest contributor: fullname: Grossman – volume: 81 start-page: 401 year: 1998 end-page: 405 ident: bib11 article-title: Allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, asthma and immunology publication-title: Ann Allergy Asthma Immunol contributor: fullname: Malling – volume: 95 start-page: 258 year: 2001 end-page: 264 ident: bib39 article-title: Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study publication-title: Respir Med contributor: fullname: Jørgensen – year: 2001 ident: bib43 article-title: Statistical considerations in analysing health care resource utilization and cost data publication-title: Economic evaluation in health care. Merging theory with practice contributor: fullname: Carides – volume: 43 start-page: 523 year: 1988 end-page: 529 ident: bib33 article-title: Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis publication-title: Allergy contributor: fullname: Østerballe – volume: 61 start-page: 855 year: 2006 end-page: 859 ident: bib17 article-title: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children publication-title: Allergy contributor: fullname: Dreborg – volume: 97 start-page: 615 year: 2006 end-page: 621 ident: bib22 article-title: Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study publication-title: Ann Allergy Asthma Immunol contributor: fullname: Crimi – volume: 25 start-page: 47 year: 2005 end-page: 53 ident: bib42 article-title: Asthma: prevalence and cost of illness publication-title: Eur Respir J contributor: fullname: Lauterbach – volume: 82 start-page: 339 year: 1999 end-page: 347 ident: bib51 article-title: Utilization and cost of immunotherapy for allergic asthma and rhinitis publication-title: Ann Allergy Asthma Immunol contributor: fullname: Platt – volume: 302 start-page: 265 year: 1991 end-page: 269 ident: bib12 article-title: Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs publication-title: BMJ contributor: fullname: Durham – volume: 101 start-page: 352 year: 1998 end-page: 356 ident: bib7 article-title: The impact of allergic rhinitis on bronchial asthma publication-title: J Allergy Clin Immunol contributor: fullname: Corren – volume: 50 start-page: 405 year: 1995 end-page: 413 ident: bib13 article-title: Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study publication-title: Allergy contributor: fullname: Durham – volume: 23 start-page: 723 year: 2004 end-page: 729 ident: bib41 article-title: Asthma severity and medical resource utilisation publication-title: Eur Respir J contributor: fullname: Neri – volume: 24 start-page: 758 year: 2004 end-page: 764 ident: bib3 article-title: Prevalence and rate of diagnosis of allergic rhinitis in Europe publication-title: Eur Respir J contributor: fullname: Durham – volume: 8 start-page: 245 year: 1995 end-page: 252 ident: bib29 article-title: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation publication-title: Pharmacoeconomics contributor: fullname: Antoñanzas – volume: 17 start-page: 13 year: 2000 end-page: 35 ident: bib44 article-title: A comparative review of generic quality-of-life instruments publication-title: Pharmacoeconomics contributor: fullname: Hays – year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib32 contributor: fullname: Drummond – volume: 109 start-page: 251 issue: 2 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib16 article-title: Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis. The PAT-study publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2002.121317 contributor: fullname: Möller – ident: 10.1016/j.rmed.2007.05.003_bib36 – ident: 10.1016/j.rmed.2007.05.003_bib2 – volume: 302 start-page: 265 issue: 6771 year: 1991 ident: 10.1016/j.rmed.2007.05.003_bib12 article-title: Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs publication-title: BMJ doi: 10.1136/bmj.302.6771.265 contributor: fullname: Varney – ident: 10.1016/j.rmed.2007.05.003_bib46 – volume: 57 start-page: 1048 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib6 article-title: The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study publication-title: Allergy doi: 10.1034/j.1398-9995.2002.23664.x contributor: fullname: Linneberg – volume: 34 start-page: 468 issue: 7 year: 1999 ident: 10.1016/j.rmed.2007.05.003_bib14 article-title: Long-term clinical efficacy of grass-pollen allergen specific immunotherapy publication-title: N Engl J Med doi: 10.1056/NEJM199908123410702 contributor: fullname: Durham – volume: 82 start-page: 339 year: 1999 ident: 10.1016/j.rmed.2007.05.003_bib51 article-title: Utilization and cost of immunotherapy for allergic asthma and rhinitis publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)63282-6 contributor: fullname: Donahue – volume: 15 start-page: 329 issue: 5 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib34 article-title: The PANDORA project: results of the cost of illness analysis publication-title: J Hum Hypertension doi: 10.1038/sj.jhh.1001178 contributor: fullname: Degli Esposti – volume: 7 start-page: 1 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib28 article-title: A proposal for Italian Guidelines in pharmacoeconomics publication-title: Pharmacoeconomics doi: 10.2165/00019053-199507010-00001 contributor: fullname: Garattini – ident: 10.1016/j.rmed.2007.05.003_bib5 – volume: 17 start-page: 13 issue: 1 year: 2000 ident: 10.1016/j.rmed.2007.05.003_bib44 article-title: A comparative review of generic quality-of-life instruments publication-title: Pharmacoeconomics doi: 10.2165/00019053-200017010-00002 contributor: fullname: Coons – volume: 20 start-page: 260 issue: 2 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib38 article-title: Persistent asthma: disease control, resource utilisation and direct costs publication-title: Eur Respir J doi: 10.1183/09031936.02.02542001 contributor: fullname: Van Ganse – volume: 43 start-page: 523 issue: 7 year: 1988 ident: 10.1016/j.rmed.2007.05.003_bib33 article-title: Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis publication-title: Allergy doi: 10.1111/j.1398-9995.1988.tb01631.x contributor: fullname: Mosbech – ident: 10.1016/j.rmed.2007.05.003_bib9 – ident: 10.1016/j.rmed.2007.05.003_bib50 – volume: 5 start-page: 43 issue: 1 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib21 article-title: Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy publication-title: Inflamm Allergy Drug Targets doi: 10.2174/187152806775269286 contributor: fullname: Passalacqua – volume: 35 start-page: 189 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib27 article-title: Guidelines for economic evaluation in Italy: recommendations from the Italian group of pharmacoeconomic studies publication-title: Drug Inf J doi: 10.1177/009286150103500122 contributor: fullname: Capri – volume: 53 start-page: 266 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib47 article-title: Airborne grass (Poaceae) pollen in southern Spain. Results of a 10-year study (1987–1996) publication-title: Allergy doi: 10.1111/j.1398-9995.1998.tb03886.x contributor: fullname: Gonzáles Minero – volume: 108 start-page: S147 issue: Suppl 5 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib1 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.118891 contributor: fullname: Bousquet – year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib43 article-title: Statistical considerations in analysing health care resource utilization and cost data contributor: fullname: Heyse – ident: 10.1016/j.rmed.2007.05.003_bib19 – volume: 37 start-page: 53 issue: 1 year: 1996 ident: 10.1016/j.rmed.2007.05.003_bib45 article-title: EuroQol: the current state of play publication-title: Health Policy doi: 10.1016/0168-8510(96)00822-6 contributor: fullname: Brooks – volume: 111 start-page: 6 year: 1997 ident: 10.1016/j.rmed.2007.05.003_bib8 article-title: One airway, one disease publication-title: Chest doi: 10.1378/chest.111.2_Supplement.11S contributor: fullname: Grossman – volume: 8 start-page: 245 issue: 3 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib29 article-title: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation publication-title: Pharmacoeconomics doi: 10.2165/00019053-199508030-00007 contributor: fullname: Rovira – ident: 10.1016/j.rmed.2007.05.003_bib30 – volume: 25 start-page: 47 year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib42 article-title: Asthma: prevalence and cost of illness publication-title: Eur Respir J doi: 10.1183/09031936.04.00116203 contributor: fullname: Stock – volume: 117 start-page: 802 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib23 article-title: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.12.1358 contributor: fullname: Durham – volume: 61 start-page: 185 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib24 article-title: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis publication-title: Allergy doi: 10.1111/j.1398-9995.2005.00949.x contributor: fullname: Dahl – volume: 59 start-page: 373 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib10 article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma publication-title: Allergy doi: 10.1111/j.1398-9995.2003.00468.x contributor: fullname: Bousquet – volume: 95 start-page: 258 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib39 article-title: Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study publication-title: Respir Med doi: 10.1053/rmed.2001.1031 contributor: fullname: Linneberg – volume: 24 start-page: 758 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib3 article-title: Prevalence and rate of diagnosis of allergic rhinitis in Europe publication-title: Eur Respir J doi: 10.1183/09031936.04.00013904 contributor: fullname: Bauchau – volume: 33 start-page: 206 issue: 2 year: 2003 ident: 10.1016/j.rmed.2007.05.003_bib15 article-title: Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study publication-title: Clin Exp Allergy doi: 10.1046/j.1365-2222.2003.01587.x contributor: fullname: Di-Rienzo – volume: 61 start-page: 855 issue: 7 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib17 article-title: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01068.x contributor: fullname: Niggemann – volume: 117 start-page: 721 issue: 3 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib18 article-title: A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2006.01.023 contributor: fullname: Valovirta – volume: 81 start-page: 401 issue: 5 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib11 article-title: Allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, asthma and immunology publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)63136-5 contributor: fullname: Bousquet – volume: 101 start-page: 352 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib7 article-title: The impact of allergic rhinitis on bronchial asthma publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(98)70218-0 contributor: fullname: Corren – volume: 114 start-page: 851 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib40 article-title: Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2004.07.012 contributor: fullname: Novembre – volume: 117 start-page: 34 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib4 article-title: Changes in the prevalence of asthma and allergies among children and adolescents in Italy: 1999–2002 publication-title: Pediatrics doi: 10.1542/peds.2004-2709 contributor: fullname: Galassi – volume: 12 start-page: 1322 issue: 6 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib37 article-title: Brugues J: cost of asthma according to the degree of severity publication-title: Eur Respir J doi: 10.1183/09031936.98.12061322 contributor: fullname: Serra-Batles – volume: 111 start-page: 437 issue: 3 year: 2003 ident: 10.1016/j.rmed.2007.05.003_bib20 article-title: Noninjection routes for immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2003.129 contributor: fullname: Canonica – volume: 59 start-page: 62 issue: 1 year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib35 article-title: Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and Spain publication-title: Int J Clin Practice doi: 10.1111/j.1742-1241.2005.00347.x contributor: fullname: Lindgren – volume: 61 start-page: 527 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib48 article-title: The use of quality-adjusted life-years in cost-effectiveness studies publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01053.x contributor: fullname: Sculpher – volume: 23 start-page: 723 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib41 article-title: Asthma severity and medical resource utilisation publication-title: Eur Respir J doi: 10.1183/09031936.04.00004904 contributor: fullname: Antonicelli – ident: 10.1016/j.rmed.2007.05.003_bib49 – volume: 16 start-page: 191 year: 2007 ident: 10.1016/j.rmed.2007.05.003_bib25 article-title: Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study publication-title: Qual Life Res doi: 10.1007/s11136-006-9110-3 contributor: fullname: Rak – volume: 118 start-page: 434 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib26 article-title: Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2006.05.003 contributor: fullname: Dahl – ident: 10.1016/j.rmed.2007.05.003_bib31 doi: 10.3833/pdr.v2005i64.620 – volume: 50 start-page: 405 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib13 article-title: Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study publication-title: Allergy doi: 10.1111/j.1398-9995.1995.tb01170.x contributor: fullname: Walker – volume: 97 start-page: 615 issue: 5 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib22 article-title: Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)61090-3 contributor: fullname: Berto |
| SSID | ssj0009440 |
| Score | 2.119543 |
| Snippet | Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass... Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced... BACKGROUNDAllergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen... |
| SourceID | proquest crossref pubmed pascalfrancis elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1885 |
| SubjectTerms | Adolescent Adult Aged Allergen specific immunotherapy Allergens - economics Allergens - therapeutic use Biological and medical sciences Conjunctivitis, Allergic - economics Conjunctivitis, Allergic - prevention & control Cost-Benefit Analysis Cost-effectiveness Desensitization, Immunologic - economics Desensitization, Immunologic - methods Drug Costs - statistics & numerical data Female Grass allergen tablet Grass pollen allergy Health Resources - utilization Humans Male Medical sciences Middle Aged Non tumoral diseases Otorhinolaryngology. Stomatology Pneumology Poaceae Pollen - immunology Prospective Studies Pulmonary/Respiratory QALY Quality-Adjusted Life Years Rhinitis, Allergic, Seasonal - economics Rhinitis, Allergic, Seasonal - prevention & control Rhinoconjunctivitis Tablets Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| Title | Cost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0954611107001904 https://dx.doi.org/10.1016/j.rmed.2007.05.003 https://www.ncbi.nlm.nih.gov/pubmed/17611095 https://www.proquest.com/docview/1035047243/abstract/ https://search.proquest.com/docview/68134246 |
| Volume | 101 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Ni9QwFA_rCiKI-G11HXPwJnXaNE3S4zi4jop7UBcGLyHJJDoLtqWdvfon-Uf4l_lem-6wyHrwUkqTtiEf7_v9HiEvyqpy3pmQusxwUFAsS80GLlbIvNwoHuxmQPs8EatT_n5drg_IcsqFwbDKSPtHmj5Q6_hkHmdz3m63888gHHCRo_6CcsqACYrYnpjEt369B97lQ1Ikdk6xd0ycGWO8OuA4EcYQTSvFVczpVmt6mLIw1rq4WhgdmNLxHXI7SpN0MQ74Ljnw9T1y42P0l98nP5ZNv0vHmI1I1mgT6NtPi6-LNf39i4LIStuI4tTU2PatA3GatmhPqCko7LD0G9p939YNaM5nwAWHchPbHtroUH_PdzUdbfoPyOnxmy_LVRoLLKSulHKXWhdMpbKKMXTGCGDnxmUeblxAYPkqs6ISMniWCebFRgVWlN546Wxp0cNaPCSHdVP7x4QK57KQGeVBQeJWMZurKmfCF9JkQZmQkJfTzOp2xNHQU4DZmcZ1wIKYUmclopUmRE6Tr6cMUaBpvo8HrNe57pnO9F-bICHlxZuX9pEGFvHPP84urfF-kKpSIGWphBxNi673o0C_LJeMw_vPL5rhgKLXxdS-Oe-1UHnBGRcJeTRulf2npUC81_LJf475Kbk5Wpox4u2IHO66c_8MRKSdnZFrr37mM3J98e7D6mQ2nIg_-MkRlg |
| link.rule.ids | 315,786,790,3525,4521,24144,27957,27958,45620,45714,45909 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqrQRICPEmUFofuKFoHcevHFcrypa2e4BWWnGxHMcuW4lklWz_Fj-CX8Y4cbqqUDlwiaI4TkZjex6e8TcIfeBFYZ01PrXEMHBQSpqaCi6lkBmvFPNl1aN9LsXikn1Z8dUemo9nYUJaZZT9g0zvpXV8Mo3cnG7W6-k3MA6YyIL_EuyUgAm6z7jM2ATtz05OF8sd9i7rz0WG99PQIZ6dGdK8WlA6Eckw7K7k9-mnxxvTAdf8UO7ifnu010vHT9GTaFDi2UDzM7Tn6ufowXkMmb9AP-dNt02HtI0o2XDj8eevs--zFf79C4PVijcRyKmpQ9tVCxY13oQthRqDzw6jX-H2x7puwHm-BkXYV5xYd9CG-xJ8rq3xsK3_El0ef7qYL9JYYyG1XMptWlpvCkUKSkM8RoBGN5Y4uLE-YMsXpBSFkN5RIqgTlfI05844aUtehiBr_gpN6qZ2bxAW1hJPjHLgI7FS0TJTRUaFy6UhXhmfoI8jZ_VmgNLQY47ZtQ7jEGpiSk14ACxNkByZr8dDoiDWXBfXWKcz3VFN9F_zIEH8tuedqaRBS_zzj4d3xnhHpCoUGFoqQQfjoOsdFSE0yyRl0P_othnWaAi8mNo1N50WKssZZSJBr4epsvu0FAHylb_9T5qP0MPFxfmZPjtZnr5Dj4aN55AAd4Am2_bGvQeLaVsexhXxB9IVEz8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-effectiveness+of+GRAZAX+%C2%AE+for+prevention+of+grass+pollen+induced+rhinoconjunctivitis+in+Southern+Europe&rft.jtitle=Respiratory+medicine&rft.au=Canonica%2C+G.W.&rft.au=Poulsen%2C+P.B.&rft.au=Vestenb%C3%A6k%2C+U.&rft.date=2007-09-01&rft.pub=Elsevier+Ltd&rft.issn=0954-6111&rft.eissn=1532-3064&rft.volume=101&rft.issue=9&rft.spage=1885&rft.epage=1894&rft_id=info:doi/10.1016%2Fj.rmed.2007.05.003&rft.externalDocID=S0954611107001904 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09546111%2FS0954611107X01884%2Fcov150h.gif |